KYTX
Kyverna Therapeutics, Inc.
There isn't enough reported data to score KYTX yet.
KYTX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
KYTX's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
KYTX PE Valuation
KYTX has no meaningful PE right now: it lost money over the past year.
KYTX Forward outlook
There aren't enough analyst estimates for KYTX to show an outlook.
KYTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.76 | +$0.83 |
| Q2 2026 | -$2.93 | +$0.61 |
| Q1 2026 | -$3.27 | -$0.03 |
| Q4 2025 | -$3.64 | -$0.31 |
| Q3 2025 | -$3.59 | -$0.52 |
| Q2 2025 | -$3.54 | -$0.91 |
| Q1 2025 | -$3.24 | -$0.98 |
| Q4 2024 | -$3.33 | -$1.76 |
KYTX lost $2.76 per share over the past year, a smaller loss than the year before.
KYTX Quarterly Revenue
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2022 | -3112% | N/A |
KYTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$35.5M | +$7.8M |
| Q1 2026 | -$41.6M | +$3.3M |
| Q4 2025 | -$33.5M | +$4.1M |
| Q3 2025 | -$43.3M | -$15.7M |
| Q2 2025 | -$32M | -$6.8M |
| Q1 2025 | -$44.9M | -$18.8M |
| Q4 2024 | -$37.6M | -$18.7M |
| Q3 2024 | -$27.6M | -$16.2M |
KYTX has burned cash in almost every quarter: −$154M over the past year, against −$142M the year before.
KYTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.7% | +1.1M shares |
| 1 year | +43% | +18.7M shares |
| 3 years | +44% | +18.8M shares |
KYTX has 62M diluted shares, up 43% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
KYTX Net Leverage
KYTX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
KYTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.6 | Neutral |
| Stochastic | 10.9 | Oversold |
KYTX's weekly RSI is 33 (neutral) and its Stochastic is 11 (oversold).
KYTX PE vs Healthcare Sector
KYTX has no meaningful PE right now: it lost money over the past year.
KYTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.76 | 13% below |
| 20 week MA | $7.06 | 29% below |
| 50 week MA | $7.90 | 36% below |
| 100 week MA | $5.88 | 14% below |
KYTX is in a downtrend: it's below all four of its weekly moving averages, and 14% below its 100-week average.
KYTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $30.1 | $3.99 | -87% |
| 2025 | $3.99 | $9.40 | +136% |
| 2026 YTD | $9.40 | $5.03 | -46% |
KYTX's yearly returns have swung widely, from +136% in 2025 to −87% in 2024. It's down 46% so far in 2026.